About
Provided by Hogan Lovells Cadwalader
Life Science team had develop capabilities through innovation and sophistication handling complex and strategical projects, operations, matters in pharma/biotech, genetic engineering, medical devices and equipment, high-tech devices, digital health, cosmetics, food, alcohol, new technologies of tobacco, controlled and toxic substances and consumer products.
Our practice has become more specialized and sophisticated on innovative transition business models resulting from global operational and corporate restructuring, launching and access of Covid-19 health inputs and safety measures, implementation and launching of high-tech platforms for long-distance medical care (telemedicine), complex food labelling, reformulation advertising matters including related high profile litigation, highly sensitive compliance matters, commercialization of regulated products through digital platforms, significant food safety and technology topics, product recalls, handling of controlled substances, good manufacturing practices´ certifications, launching of innovative products for the tobacco industry, product liability, advice concerning complex GMO´s products and planning of regulatory strategies in significant and sensitive transactions and operations, ethical and anticorruption compliance issues in pharma/biotech industry, Cannabis, patent litigation; unfair competition actions; administrative procedures and data privacy matters, clinical trials, as well as diversified strategical litigation.
